Insomnia Market Report 2026

The insomnia market size has grown strongly in recent years. It will grow from $5.22 billion in 2025 to $5.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of sleep disorders, increased stress and lifestyle changes, widespread use of benzodiazepines and sedatives, growing diagnosis rates of insomnia, expansion of sleep clinics and specialists.

The insomnia market size is expected to see strong growth in the next few years. It will grow to $7.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of digital therapeutics, growing demand for safer long-term insomnia treatments, rising geriatric population, increasing mental health awareness, expansion of online and retail pharmacy access. Major trends in the forecast period include growing adoption of non-pharmacological insomnia treatments, rising use of cognitive behavioral therapy for insomnia, increasing preference for personalized sleep management, expanding use of combination therapy approaches, growing awareness of chronic insomnia as a medical condition.

The rising prevalence of chronic diseases is expected to drive growth in the insomnia market in the coming years. Chronic diseases are illnesses that last three months or more and may worsen over time. Individuals with chronic conditions, such as cardiovascular disorders, diabetes, and chronic pain, often experience insomnia or other sleep-related issues as a comorbidity. This increasing prevalence creates demand for effective insomnia treatments and management strategies, boosting the market for products and services addressing sleep disorders. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that 76.4% of US adults - approximately 194 million people - had one or more chronic conditions in 2023, with prevalence rates of 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, the growing prevalence of chronic diseases is supporting expansion in the insomnia market.

Leading companies in the insomnia market are introducing innovative products, such as zaleplon-based insomnia medications, to gain a competitive edge. Zaleplon is a non-benzodiazepine sedative-hypnotic used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co. Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea featuring zaleplon as its active ingredient. Zaleplon is FDA-approved, with rapid onset of action, a short half-life, and minimal disruption to daytime activities. With rising insomnia prevalence, Zaledeep Cap. provides an effective treatment option to improve sleep quality and overall well-being.

In October 2023, dsm-firmenich N.V., a Netherlands-based health and nutrition science company, partnered with Bod Science Pty Ltd to advance the development of one of the world’s first cannabidiol (CBD)-based insomnia treatments. This partnership aims to progress Bod Science’s investigational cannabinoid therapy, leverage dsm-firmenich’s GMP-certified pharmaceutical-grade CBD active ingredient for clinical and regulatory development, expand consumer access through emerging over-the-counter pathways in Australia, and accelerate the launch of an innovative sleep-focused therapeutic option. Bod Science Pty Ltd is an Australia-based medical cannabis company specializing in evidence-based CBD formulations for sleep and wellness.

Major companies operating in the insomnia market are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.

North America was the largest region in the insomnia market in 2025. The regions covered in the insomnia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insomnia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the insomnia market by increasing costs of pharmaceutical ingredients, medical devices, and digital health hardware used in insomnia treatment. These impacts are most visible in pharmacological therapy and device-based treatment segments, particularly across asia-pacific and europe where reliance on imported components is high. Higher tariffs have raised treatment costs for healthcare providers and patients. However, tariffs are also encouraging domestic drug manufacturing, local device production, and investment in cost-effective digital therapeutics, supporting long-term market sustainability.

The insomnia market research report is one of a series of new reports that provides insomnia market statistics, including insomnia industry global market size, regional shares, competitors with a insomnia market share, detailed insomnia market segments, market trends and opportunities, and any further data you may need to thrive in the insomnia industry. This insomnia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Insomnia is a sleep disorder characterized by difficulty in falling asleep or staying asleep. The condition can be classified as short-term (acute) or long-term (chronic) based on its duration. Treatments for insomnia include drugs, digital therapeutics, and medical devices.

The main therapy types for insomnia are non-pharmacological and pharmacological interventions. Non-pharmacological interventions (NPIs) involve non-chemical approaches that benefit the patient, such as light therapy and exercise. Pharmacological therapies include drug classes such as antidepressants, melatonin antagonists, benzodiazepines, non-benzodiazepines, orexin antagonists, and others. These treatments are administered via routes such as oral or parenteral delivery and are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.